Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma.

نویسندگان

  • Graham P Collins
  • Anne N Parker
  • Christopher Pocock
  • Irfan Kayani
  • Anna Sureda
  • Tim Illidge
  • Kirit Ardeshna
  • David C Linch
  • Karl S Peggs
چکیده

Department of Haematology, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, HPC Transplant Programme, Beatson West of Scotland Cancer Centre, Glasgow, Department of Haematology, East Kent Hospitals NHS Trust, Canterbury, Department of Nuclear Medicine, University College London Hospitals NHS Trust, London, Department of Haematology, Addenbrookes Hospital, Cambridge University, Cambridge, Institute of Cancer Sciences, University of Manchester, The Christie Hospital, Manchester, Department of Haematology, University College London Hospitals NHS Trust, London, and Department of Haematology, UCL Cancer Institute, University College London, London, UK

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Development of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma

NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...

متن کامل

Treatment of Newly Diagnosed and Relapsed Hodgkin Lymphoma in Children

Hodgkin lymphoma (HL) accounts for about 10% of all childhood cancers. Five-year survival rates with modern therapies are now approaching >90-95% as a consequence of its significant sensitivity to both chemotherapy and radiation. The current challenge is to determine how much therapy is needed to improve survival and how to adapt treatment to the patient to prevent these long term toxicities. T...

متن کامل

Development of DOTA-Rituximab kit formulation to be labeled with 90Y for radioimmunotherapy of B-cell Non-Hodgkin Lymphoma

NHL is the most common hematologic cancer in adults. Rituximab is the FDA approved treatment of relapsed or refractory low grade B-cell Non-Hodgkin Lymphoma (NHL). But patients eventually become resistant to rituximab. Since lymphocytes and lymphoma cells are highly radiosensitive, low grade NHL that has relapsed or refractory to standard therapy is treated by RIT in which a beta-emitting radio...

متن کامل

Pancreatic adenocarcinoma in a patient with relapsed Hodgkin’s lymphoma

After curative treatment of Hodgkin’s lymphoma, increased risk of certain solid tumors has been reported. To best of our knowledge this is the first report of metachronous pancreatic adenocarcinoma which developed outside the previous radiation field in a patient with relapse Hodgkin’s lymphoma. Herein we present an 81-year-old female who developed pancreatic adenocarcinoma four yea...

متن کامل

Primary Cervical Non-Hodgkin Lymphoma; A Narrative Review

Gynecological lymphoma is one of the rarest tumors of the female organs that need to be kept in mind in a suspected patient due to its different management protocol. Even though the reported cases of ovarian lymphoma are not limited; our knowledge about diagnosis and treatment of primary cervical lymphoma is restricted. There is a rising number of suggested imaging and pathological criteria tha...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • British journal of haematology

دوره 164 1  شماره 

صفحات  -

تاریخ انتشار 2014